Most home health owners think of quality scores as a clinical scoreboard — something the director of nursing watches, not something that shows up in an enterprise value. Under the expanded Home Health Value-Based Purchasing (HHVBP) Model, that is no longer true. Quality is now wired directly into your Medicare payments, and through them into your EBITDA and your sale multiple.
This guide explains what the expanded HHVBP Model is, how the payment adjustment flows through to valuation, what buyers actually diligence, and what sellers can do about their score before they go to market.
HHVBP ties a portion of Medicare home health fee-for-service payments to performance on quality. The original HHVBP Model ran in nine states from 2016 through 2021. The expanded model went nationwide beginning in CY2023, making every Medicare-certified home health agency in the country a participant.
The mechanics every buyer’s diligence team already understands:
The practical takeaway: HHVBP is not a bonus program you can ignore. It is a permanent feature of Medicare home health economics that moves real dollars on your top line.
Home health is a thin-margin business. Most agencies operate on single-digit to low-teens EBITDA margins, so a payment adjustment measured in percentage points of Medicare FFS revenue is not a rounding error — it is a direct hit or boost to the bottom line.
Consider an agency with meaningful traditional Medicare fee-for-service revenue:
When a buyer capitalizes your earnings at a multiple, that quality-driven swing is multiplied. A few points of margin created or destroyed by HHVBP, capitalized at a home health multiple, can move enterprise value by far more than the raw dollar adjustment. This is why sophisticated acquirers model your TPS trajectory, not just your trailing financials.
The TPS is assembled from three categories of measures, and each tells a buyer something different about your business:
Scoring rewards both achievement (performance against a national benchmark) and improvement (performance against your own baseline). A practical consequence: an agency that starts from a low baseline and improves can still earn meaningful points — useful framing for a seller who has been investing in quality recently.
Alongside HHVBP, buyers will pull your public Quality of Patient Care star rating and HHCAHPS survey star rating. These star ratings are not the HHVBP score itself, but they are visible to referral sources and acquirers and reinforce the same story about clinical strength.
In a 2026 Medicare home health diligence process, expect acquirers to:
A clean, improving quality story shortens diligence and supports the top of your valuation range. A weak or erratic one invites reps, holdbacks, and a discount.
For a Medicare-certified home health agency, quality performance has become one of the clearest non-financial value drivers, sitting alongside payer mix and Medicare Advantage exposure:
If your agency carries significant Medicare Advantage exposure as well, the two stories compound — MA already pressures per-episode rates, and a weak HHVBP score adds rate risk on the FFS side. For the full picture on the MA side of that equation, see our guide on Medicare Advantage and home health valuation, and on the broader payer question, payer mix and home care valuation.
Quality scores move slowly, so the time to act is well before a sale process begins:
Because HHVBP performance and the resulting adjustment attach to your CMS Certification Number (CCN), deal structure matters:
This mirrors the structuring logic that already governs Medicare certification in a sale. For the mechanics of how certifications move, see selling a Medicare-certified home health agency and our overview of asset sale vs. stock sale.
HHVBP turned home health quality from a clinical scoreboard into a financial one. Your Total Performance Score now influences your Medicare revenue, your EBITDA, and — once a buyer capitalizes that EBITDA — your enterprise value. In 2026, the agencies that command premium multiples are the ones that can show a strong, improving, well-documented quality story and connect it directly to durable Medicare revenue.
If you own a Medicare-certified home health agency and are thinking about a sale in the next 12 to 24 months, your quality performance is part of your valuation today — not just your compliance file. To understand how your HHVBP standing and the rest of your profile translate into a number, book a free confidential call with our team, or explore our Medicare-certified home health M&A guidance.
Pediatric Home Health Agency Valuation in 2026: A Complete Guide
Valuation InsightsHome Care vs. Home Health vs. Hospice: EBITDA Multiples Compared (2026)
Market IntelligenceWhat Public Home Health & Home Care Company Valuations Mean for Private Sellers
Seller GuidesCMS Enrollment Moratoria and Home Health & Hospice M&A: A 2026 Seller's Guide
Seller GuidesCMS Change of Ownership (CHOW) for Home Health & Hospice: A Seller's Guide
RegulatoryCertificate of Need (CON) States Home Health M&A Guide
Newsletter
Receive new articles, EBITDA benchmark updates, and deal intelligence directly in your inbox. No spam — unsubscribe anytime.
Join 1,200+ home care executives. Unsubscribe anytime.